clinical

In today's episode, Naila provides an overview of 14 articles published in November 2023 on non-pharmacological interventions for AD. You'll hear about cognitive training, music therapy, chair yoga, providing support to caregivers, and a range of neural stimulation techniques. Enjoy!

Cognitive and Social Factors (2:26)

Lifestyle interventions (13:40)

Stimulation Techniques (19:20)

-------------------------------------------------------------- 

You can find the bibliography for this episode here, or by clicking the link below:

https://drive.google.com/file/d/1A4HZVCtgh5AwZkd5V2ATZSFAxGJt48q3/view?usp=drive_link

To access the folder with ALL our bibliographies, follow this link (it will be updated as we publish episodes and process bibliographies), or use the link below:

https://drive.google.com/drive/folders/1bzSzkY9ZHzzY8Xhzt0HZfZhRG1Gq_Si-?usp=sharing

You can also find all of our bibliographies on our website: amindr.com. 

-------------------------------------------------------------- 

Follow-up on social media for more updates!

Twitter: @AMiNDR_podcast

Instagram: @AMiNDR.podcast

Facebook:  AMiNDR  

Youtube: AMiNDR Podcast

LinkedIn: AMiNDR Podcast

Email: amindrpodcast@gmail.com  

-------------------------------------------------------------- 

Please help us spread the word about AMiNDR to your friends, colleagues, and networks! And if you could leave us a rating and/or review on your streaming app of choice (Apple Podcasts, Spotify, or wherever you listen to the podcast), that would be greatly appreciated! It helps us a lot and we thank you in advance for leaving a review! Don’t forget to subscribe to hear about new episodes as they come out too. 

Thank you to our sponsor, the Canadian Consortium of Neurodegeneration in Aging, or CCNA, for their financial support of this podcast. This helps us to stay on the air and bring you high quality episodes. You can find out more about the CCNA on their website: https://ccna-ccnv.ca/. 

Our team of volunteers works tirelessly each month to bring you every episode of AMiNDR. This episode was scripted and hosted by Naila Kuhlmann and Christy Yu, edited by Scott Prins, and reviewed by Anusha Kamesh. The bibliography was made by Rob Cloke and wordcloud was created by Salodin Al-Achkar (www.wordart.com). 

Big thanks to the sorting team for taking on the enormous task of sorting all of the Alzheimer’s Disease papers into episodes each month. For November 2023, the sorters were Elyn Rowe, Christy Yu, Salodin Al-Achkar, Naila Kuhlmann and Anusha Kamesh. Also, props to our management team, which includes Sarah Louadi, Ellen Koch, Naila Kuhlmann, Elyn Rowe, Anusha Kamesh, Lara Onbasi, Joseph Liang, Judy Cheng, and Christy Yu, for keeping everything running smoothly. AMiNDR was founded in 2020 by Sarah Louadi, Ellen Koch, Elyn Rowe, and Naila Kuhlmann. 

Our music is from "Journey of a Neurotransmitter" by musician and fellow neuroscientist Anusha Kamesh; you can find the original piece and her other music on soundcloud under Anusha Kamesh or on her YouTube channel, AKMusic.   

https://www.youtube.com/channel/UCMH7chrAdtCUZuGia16FR4w   

-------------------------------------------------------------- 

If you are interested in joining the team, send us your CV by email. We are specifically looking for help with sorting abstracts by topic, abstract summaries and hosting, audio editing, creating bibliographies, and outreach/marketing. However, if you are interested in helping in other ways, don't hesitate to apply anyways.  

--------------------------------------------------------------

*About AMiNDR: *  

Learn more about this project and the team behind it by listening to our first episode: "Welcome to AMiNDR!" 

Anne Tebo, Ph.D., explains how Mayo Clinic Laboratories' new serum tests help overcome the challenges of diagnosing primary biliary cholangitis, or PBC. Test results can guide clinical care for patients with this life-threatening autoimmune liver disease.

(00:32)
Could you please provide a little information about your background?

(02:09)
Please give a brief overview of the new test panels.

(05:35)
Which patients should have this testing and when should it be performed?

(09:49)
What alternative test options are available, and how do those compare to our testing at Mayo Clinic Laboratories?

(13:15)
How are the results used in patient care?

Joshua Bornhorst, Ph.D., explains how Mayo Clinic Laboratories' unique blood test identifies pregnant women at risk of developing preeclampsia with severe features. Test results can guide clinical management, to safeguard maternal and neonatal health.

Speaker 3: (00:32)
Can you share a little about yourself and your background?

Speaker 3: (01:00)
Can you provide us with an overview of this new preeclampsia assay?

Speaker 3: (02:33)
Can you share what will be reported with this assay?

Speaker 3: (03:07)
Which patients should have this testing and at what point should it be performed?

Speaker 3: (03:35)
Can you share what alternative test options are available today for preeclampsia?

Speaker 3: (03:52)
How are the test results used in patient care?

As we get back up to speed on our regular episodes, we thought we'd treat you (and ourselves) to something out of the ordinary: a conversation on how visual storytelling can shape how we think - and feel - about Alzheimer's disease. Host Naila Kuhlmann had the pleasure of interviewing Gina Martin, who founded the Bob and Diane Fund to support and promote visual storytelling about Alzheimer's and dementia. Tune in to get the backstory on the fund, an auditory glimpse at the work of this year's winner, a discussion on the social narrative of Alzheimer's disease, and reflections on the role of the arts in shaping it. We hope you enjoy, and welcome your feedback and thoughts!

Links:

Bob and Diane Fund Website

Bob and Diane Fund 2023 Winner

Piece of Mind: Virtual Performance on Dementia

To access the folder with ALL our bibliographies from past episodes, follow this link (it will be updated as we publish episodes and process bibliographies), or use the link below:

https://drive.google.com/drive/folders/1bzSzkY9ZHzzY8Xhzt0HZfZhRG1Gq_Si-?usp=sharing

You can also find all of our bibliographies on our website: amindr.com. 

-------------------------------------------------------------- 

Follow-up on social media for more updates!

Twitter: @AMiNDR_podcast

Instagram: @AMiNDR.podcast

Facebook:  AMiNDR  

Youtube: AMiNDR Podcast

LinkedIn: AMiNDR Podcast

Email: amindrpodcast@gmail.com  

-------------------------------------------------------------- 

Please help us spread the word about AMiNDR to your friends, colleagues, and networks! And if you could leave us a rating and/or review on your streaming app of choice (Apple Podcasts, Spotify, or wherever you listen to the podcast), that would be greatly appreciated! It helps us a lot and we thank you in advance for leaving a review! Don’t forget to subscribe to hear about new episodes as they come out too. 

Our team of volunteers works tirelessly each month to bring you every episode of AMiNDR. This episode was hosted by Naila Kuhlmann, edited by Michelle Grover, and reviewed by Naila Kuhlmann. The episode art was created by Salodin Al-Achkar (www.wordart.com). 

Big thanks to the sorting team for taking on the enormous task of sorting all of the Alzheimer’s Disease papers into episodes each month. For November 2023, the sorters were Elyn Rowe, Christy Yu, Salodin Al-Achkar, Naila Kuhlmann and Anusha Kamesh. Also, props to our management team, which includes Sarah Louadi, Ellen Koch, Naila Kuhlmann, Elyn Rowe, Anusha Kamesh, Lara Onbasi, Joseph Liang, Judy Cheng, and Christy Yu, for keeping everything running smoothly. AMiNDR was founded in 2020 by Sarah Louadi, Ellen Koch, Elyn Rowe, and Naila Kuhlmann. 

Our music is from "Journey of a Neurotransmitter" by musician and fellow neuroscientist Anusha Kamesh; you can find the original piece and her other music on soundcloud under Anusha Kamesh or on her YouTube channel, AKMusic.   

https://www.youtube.com/channel/UCMH7chrAdtCUZuGia16FR4w   

-------------------------------------------------------------- 

If you are interested in joining the team, send us your CV by email. We are specifically looking for help with sorting abstracts by topic, abstract summaries and hosting, audio editing, creating bibliographies, and outreach/marketing. However, if you are interested in helping in other ways, don't hesitate to apply anyways.  

--------------------------------------------------------------

*About AMiNDR: *  

Learn more about this project and the team behind it by listening to our first episode: "Welcome to AMiNDR!" 

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by Elitza Theel, Ph.D., director of the Infectious Diseases Serology Laboratory at Mayo Clinic, to talk about the sexually-transmitted disease syphilis. 

Specific topics of discussion include:

• The history, cause, and symptoms of syphilis.
• A rare recent outbreak of ocular syphilis cases.
• The dramatic rise in syphilis and congenital syphilis cases in the United States over the last few years.
• The variety of syphilis testing options.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to welcome the new year and discuss the increase of respiratory viruses.

Their discussion includes:

• The increasing number of COVID-19 and influenza cases across the United States.
• The endemic state of COVID-19 and tools for prevention.
• The continued need to protect public health and advocate for the reauthorization of the Pandemic and All-Hazards Preparedness Act.

Devin Oglesbee, Ph.D., explains how Mayo Clinic Laboratories' cholestasis gene panel identifies mutations that cause low flow of bile from the liver. Test results help guide treatment decisions that can prevent liver damage.

Show notes
(00:32)
 Could you please provide us a little information about your background?

(01:46)
 Could you please give the audience a brief overview of this assay?

(03:45)
 Which patients should have this testing and when should it be performed?

(06:39)
 How are the results used in patient care?

(08:51)
 What alternative test options are available and how do they compare to our test?

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss the U.S. Food and Drug Administration’s (FDA) proposed rule on laboratory-developed tests (LDTs) and the comments Mayo Clinic submitted to the FDA.

Their discussion includes:

• How Mayo Clinic responded in its comments to the FDA on the proposed rule on LDTs.
• What comes next after the public comment period has closed effective Dec. 4.
• Quality management systems that are currently in place for laboratories.
• How changes in regulation could impact laboratory operations, patient care, access to testing, and innovation.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss strategies for responsible innovation and how new standards for artificial intelligence (AI) safety will impact laboratory medicine and diagnostics.

Their discussion includes:

• Highlights of the Executive Order issued by President Biden on Oct. 30 that establishes new standards for safe and secure AI development. 
• Ethical considerations for laboratory leaders when applying AI algorithms.
• The importance of ensuring equitable access to powerful healthcare tools like AI.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss the recent news of a possible cure for sickle cell disease, as well as gene editing therapies and their impact on the laboratory. 

Their discussion includes:

• Characteristics of sickle cell disease and current testing and treatment options.
• Advantages, challenges, and ethical considerations for gene editing tools.
• How gene therapies may impact the laboratory and the process for testing specimens.
• How the high cost of innovative therapeutics may accentuate disparities in care.

Welcome back to Action Potential, join us this week as we welcome Dr. Paul Komenda, Chief Medical Officer, of Quanta Dialysis Technologies

What you'll get from this episode:

• Dr. Paul Komenda's path from nephrologist to dialysis tech innovator.
• Home hemodialysis program initiated by Dr. Komenda in Winnipeg.
• Impact of remote physiological monitoring in home hemodialysis.
• Technology's role in individualized education and support for CKD patients.
• Need for policy frameworks and investments to drive CKD care innovations.
• Envisioning nephrology's future with tech advancements and multidisciplinary collaboration.

Thank you to our sponsor ProtonIntel: “At ProtonIntel, we are building the first real-time, continuous potassium monitoring wearable, allowing clinicians to treat and manage kidney disease patients more safely and precisely. Life-saving treatments that cannot be deployed when patients have dangerous K+ levels today will be unlocked for safe and optimal use."

Learn more about Dr. Komenda: https://www.linkedin.com/in/paul-komenda-9536a924/?originalSubdomain=ca
And for more on Quanta Dialysis Technologies: https://www.quantadt.com/

Follow Action Potential: https://www.linkedin.com/company/action-potential-podcast/about/

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss current focus areas found across the diagnostics industry and what transformative technologies are being explored around the world.

Their discussion includes:

• What international laboratories and diagnostics companies are working on during this post-pandemic time.
• How large language models, artificial intelligence, and automation are accelerating changes in healthcare. 
• Considerations for thoughtful implementation of new technologies and the role pathologists and laboratorians play in keeping the needs of the patient first.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, is joined by Matthew Binnicker, Ph.D., director of the Clinical Virology Laboratory at Mayo Clinic, to discuss the seasonal outlook of respiratory viruses, including influenza, COVID-19, and respiratory syncytial virus (RSV).

Specific topics of discussion include:

• What respiratory viruses are currently circulating, and what we might expect in the coming months.
• Different testing methods for influenza, COVID-19, and RSV.
• Updated vaccination options and prevention methods.
• How to verify accurate expiration dates for at-home COVID-19 tests using the FDA website.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, is joined by Nancy Wengenack, Ph.D., director of the Mycology and Mycobacteriology Laboratories at Mayo Clinic, to talk about leprosy and why it’s been in the news recently. Leprosy, also known as Hansen’s disease, is a rare infectious disease caused by the bacteria Mycobacterium leprae.

Specific topics of discussion include:

• How leprosy is transmitted, detected, diagnosed, and treated.
• Challenges that healthcare professionals face in identifying leprosy.
• Debunking leprosy myths.

Patients with elevated LDL or "bad" cholesterol face even greater risk if their levels of small dense LDL cholesterol are also high. Vlad Vasile, M.D., Ph.D., and Leslie Donato, Ph.D., explain how Mayo Clinic Laboratories' sdLDL-c assay measures concentrations of the small dense LDL subtype, to better guide clinical care.

(00:32)
 Could you both tell us a little about yourselves and your backgrounds?

(01:24)
 Could you tell us a little bit about small dense LDL cholesterol and why it is an important marker for helping a physician understand a patient's risk for coronary heart disease?

(03:22)
 Could you describe the types of patients who could benefit from having a better understanding of their sdLDL-c levels?

(04:36)
 Could you help us understand other tests or methodologies that are currently used to assess cardiovascular risk?

(06:13)
 Could you describe Mayo Clinic's new assay for sdLDL-c cholesterol and how it will benefit physicians managing CVD patients?

Wei Shen, Ph.D., explains how Mayo Clinic Laboratories' new breast cancer panel provides rapid results to guide critical treatment decisions.

(00:32)
 Could you provide our listeners with a little bit about yourself and your background?

(01:28)
 Could you give us a brief overview of the new rapid hereditary breast cancer panel?

(03:42)
 Can you describe a little bit of the rationale behind the design and how it differs from similar tests?

(05:03)
 Can you tell us a little bit more about which patients should have this testing?

(06:00)
 How are the results of the hereditary breast cancer panel used in patient care?

(08:14)
 Is there anything else you would like to add about the panel?

Sounak Gupta, M.B.B.S., Ph.D., explains how Mayo Clinic Laboratories' gynecological NGS panels provide focused assessments of gynecological cancers. The cost-effective tests fill the gap between single gene assays and large cancer panels, to inform prognosis and treatment.
 
(00:32)
 Could you provide our listeners with a little bit about yourself and your background, please?

(01:22)
 Could you give a brief overview of the new assays?

(03:55)
 Can you talk a little about both the ovarian and gynecologic panel that will be in the new set of tests?

(05:53)
 What patients will be impacted by this testing?

(07:51)
 Can you speak to some of the individual genes in the gynecological area, such as POLE?

(09:31)
 Is there anything else you would like to add?

Sounak Gupta, M.B.B.S., Ph.D., explains how Mayo Clinic Laboratories' urologic panels efficiently inform prognosis and individualized cancer treatment. The carefully curated panels fill the void between single gene assays and large NGS panels.

(00:32)
 Could you provide our listeners with a little bit about yourself and your background, please?

(01:35)
 Could you give us a brief overview of the newly developed urologic assays?

(03:51)
 Can you talk a little bit more about what patients should have this testing?

(07:24)
 Can you talk in more detail about the MayoComplete bladder and prostate panel?

(11:33)
 How are these results used in patient care?

(16:10)
 Is there anything else you would like to add?

Angela Pickart, M.S., CGC, and Emily Lauer, M.S., CGC, explain how Mayo Clinic Laboratories' multigene panel helps identify the cause of hereditary ataxia. Precise diagnosis of this complex movement disorder helps guide patient treatment and family screening.

Show notes
Speaker 3: (00:31)
 Can you tell us a little about yourselves and your backgrounds?

Speaker 3: (01:33)
 Why is genetic counseling so important to our doctors and patients?

Speaker 3: (03:04)
 Can you give a brief overview of hereditary ataxia? 

Speaker 3: (04:24)
 Can you tell us more about Mayo Clinic's suite of molecular tests for various types of ataxia?

Speaker 3: (08:03)
 Are there any additional tests for hereditary ataxia at Mayo Clinic?

Speaker 3: (09:05)

When might a provider consider genetic testing for a patient?

Speaker 3: (10:05)
 Why is genetic testing important, and how are the results used?

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss broader changes that are unfolding in the national and global diagnostic industry, and what to expect in the coming years.

Specific topics of discussion include:

• Reflecting on Dr. Morice’s recent participation in Executive War College and what’s on the minds of other diagnostic leaders.
• Thinking beyond the COVID-19 pandemic and about the future of diagnostics through a broader aperture.
• Understanding the international healthcare and laboratory medicine industries, and thoughts from Dr. Morice’s recent visit to Singapore.